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Summary
Background: Opioids are often prescribed for pain in cirrhosis and may increase the 
risk of hepatic encephalopathy (HE).
Aim: To assess the association between opioids and HE in patients with well-com-
pensated cirrhosis.
Methods: We used the IQVIA PharMetrics (Durham, NC) database to identify pa-
tients aged 18-64 years with cirrhosis. We excluded patients with any decom-
pensation event from 1 year before cirrhosis diagnosis to 6 months after cirrhosis 
diagnosis. Over the 6 months after cirrhosis diagnosis, we determined the duration of 
continuous opioid use and classified use into short term (1-89 days) and chronic (90-
180 days). We assessed whether patients developed HE over the subsequent year (ie 
6-18 months after cirrhosis diagnosis). We used a landmark analysis and performed 
multivariable Cox proportional hazards regression to assess associations between 
opioid use and HE, adjusting for relevant confounders.
Results: The cohort included 6451 patients with compensated cirrhosis, of whom 
23.3% and 4.7% had short-term and chronic opioid prescriptions respectively. Over 
the subsequent year, HE occurred in 6.3% patients with chronic opioid prescriptions, 
5.0% with short-term opioid prescriptions and 3.3% with no opioid prescriptions. 
In the multivariable model, an increased risk of HE was observed with short-term 
(adjusted hazard ratio, HR 1.44, 95% CI 1.07-1.94) and chronic opioid prescriptions 
(adjusted HR 1.83, 95% CI 1.07-3.12) compared to no opioid prescriptions.
Conclusion: In this national cohort of privately insured patients with cirrhosis, opioid 
prescriptions were associated with the risk of incident HE. Opioid use should be mini-
mised in those with cirrhosis and, when required, limited to short duration.
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1  | INTRODUC TION
Hepatic encephalopathy (HE) is a debilitating and common com-
plication of cirrhosis.1 HE is independently associated with de-
creased health-related quality of life and reduced survival.2,3 
Sedating and psychoactive medications such as opioids may con-
tribute to the risk of HE through multiple mechanisms. For exam-
ple, opioids could lead to altered gut microbiota, upregulation in 
central mu-opioid receptors and slowed intestinal motility, which 
could increase intestinal absorption of ammonia and inflammatory 
mediators.4-7 Despite their potential harms, opioid use is frequent 
and increasing over time in patients with cirrhosis, possibly due 
to the avoidance of nonsteroidal anti-inflammatory drugs and ac-
etaminophen in these patients.8-13 In an era of increasing opioid 
use, the relative risk of HE among patients taking opioids remains 
unclear.8
Studies examining the association between opioids and HE 
have been conflicting and there have been no studies demon-
strating an association between opioids and HE in younger pa-
tients with well-compensated cirrhosis. A study within the United 
States Medicare population demonstrated that opioid prescrip-
tions were associated with increased incidence of HE.14 However, 
given the data source, this population was older and may have 
been more susceptible to centrally acting medications due to de-
creased baseline cognitive reserve. It may be that younger pa-
tients with cirrhosis are able to safely tolerate opioids. In fact, 
one single-centre study reported that an opioid prescription at 
discharge increased overall readmissions, but not hepatic enceph-
alopathy-related readmissions over 6 months.6 Furthermore, in 
a longitudinal cohort of United States veterans, baseline opioid 
use was not found to be an independent predictor of hepatic 
encephalopathy.15
Therefore, given the uncertain association between opioids and 
HE, we aimed to assess the association between opioid use and in-
cident hepatic encephalopathy among a nationally representative 
cohort of younger, privately insured patients with no prior decom-
pensation events. We also aimed to assess whether duration of 
opioid prescription influences the risk of HE. We hypothesised that 
opioid prescriptions and particularly chronic use would be associ-
ated with incident HE.
2  | MATERIAL S AND METHODS
2.1 | Data source
Our data source was the IQVIA Pharmetrics (Durham, NC) database 
from 1 January 2007 to 30 September 2015. This database includes 
claims data on pharmacy and medical coverage for more than 27 
million Americans with private health insurance. This data source 
has been used by others and has been demonstrated to be demo-
graphically representative of commercially insured US patients.16 
Given that data were obtained from a de-identified database, the 
University of North Carolina Institutional Review Board deemed this 
project to be exempt from full review.
2.2 | Patient population
We identified all patients aged 18-64 years with cirrhosis, defined as 
the presence of two or more International Classification of Diseases, 
Ninth Revision (ICD-9) codes for cirrhosis (571.5 or 571.2) on sepa-
rate dates. Previous validation studies have demonstrated that the 
presence of two outpatient ICD-9 codes improves the positive pre-
dictive value of correctly identifying cirrhosis based on a gold stand-
ard of medical record review.17,18 The ‘diagnosis date’ of cirrhosis 
was defined as the first ICD-9 code present in the database.
We limited our analysis to patients without prior decompen-
sation events, allowing us to capture truly incident HE events in a 
population with newly identified cirrhosis. In order to define this 
well-compensated population, we excluded patients with any ICD-9 
codes, Current Procedural Terminology codes or pharmacy claims 
for HE, varices/variceal haemorrhage, spontaneous bacterial perito-
nitis, ascites, hepatorenal syndrome/end-stage renal disease, hepa-
tocellular carcinoma, transjugular intrahepatic portosystemic shunt 
procedure or jaundice (Table S1). We also excluded patients who un-
derwent prior liver transplantation.
We required at least 12 months of continuous health plan enrol-
ment with pharmacy benefits before the diagnosis of cirrhosis. This 
run-in period was used to determine patient demographics, comor-
bidities, aetiology of cirrhosis (alcohol-related liver disease [ALD], 
viral hepatitis, other), complications of liver disease and other med-
ications (Tables S1 and S2). Additionally, we required 18 months of 
continuous health plan enrolment with pharmacy benefits after the 
diagnosis of cirrhosis. We limited enrolment to those ≤64 years old 
to avoid patients with dual Medicare enrolment whose claims may 
not be captured accurately in this database.
2.3 | Exposure assessment
Our exposure was defined as a claim for a prescription opioid in the 
outpatient setting over the 6 months after cirrhosis diagnosis. The 
6-month exposure period was chosen a priori to provide sufficient 
power to assess the association between opioid prescriptions and 
HE and to reduce the risk of confounding by indication and misclas-
sification of opioid use. We performed sensitivity analyses using ex-
posure periods of 3 and 9 months.
The primary analysis included all opioids listed in Table S2 and a 
sensitivity analysis excluded tramadol and propoxyphene. We cat-
egorised opioid prescriptions as short term (1-89 days) and chronic 
(≥90 days) based on the longest continuous opioid prescription re-
corded, allowing gaps of up to 7 days. Additional information on the 
assessment of exposures is shown in Figure 1.
654  |     MOON et al
2.4 | Outcome assessment
Our primary outcome was time to incident hepatic encephalopathy 
occurring from 6 to 18 months after cirrhosis diagnosis. We defined 
HE as the presence of at least one ICD-9 code (572.2) and/or pre-
scription for lactulose or rifaximin. We used a combination of ICD 
codes and medications given the low negative predictive value of 
ICD codes alone for identifying HE episodes.19,20
We performed a secondary analysis examining the association 
between opioid prescriptions and any episode of non-HE decom-
pensation event (composite outcome): variceal haemorrhage, as-
cites, spontaneous bacterial peritonitis, hepatorenal syndrome or 
placement of transjugular intrahepatic portosystemic shunt (pre-
sumably for variceal haemorrhage or ascites) (Table S1).
2.5 | Sensitivity analyses
We performed several sensitivity analyses to assess internal validity 
of the database. We first assessed the association between positive 
and negative control medications and HE. Positive controls (ie ac-
tive comparators) are medications that may be used to treat pain and 
thus evaluate for unmeasured confounders common among those 
with pain.21,22 Our positive controls were tricyclic antidepressants 
and gabapentin. Negative controls are medications that are not pre-
scribed for pain and unlikely to cause the outcome of interest. Our 
negative controls, which included statins and levothyroxine, can as-
sess for healthy user bias or confounding by selective prescribing. 
These biases result due to preferential prescribing of medications for 
patients who are healthier at baseline and avoidance of prescribing 
among those who are frail or particularly ill. Lastly, we assessed ben-
zodiazepine use given that these medications are often used in com-
bination with opioids and may confound the relationship between 
opioids and HE. In these analyses, we examined the adjusted haz-
ard ratios (HRs) for models where an additional category of ‘control 
drug only’ (eg gabapentin, tricyclic antidepressants, levothyroxine, 
statins, benzodiazepines) was added to the exposure definition.
Additionally, we performed a sensitivity analysis employing a 
true new user design, in which we excluded patients with an opioid 
prescription within the 6 months prior to cirrhosis diagnosis.
2.6 | Statistical analysis
We assessed baseline characteristics among those with no opioid 
prescriptions, short-term prescriptions and chronic opioids prescrip-
tions. For continuous variables, we reported medians with interquar-
tile ranges and reported proportions for categorical variables. We 
performed bivariate comparisons by opioid exposure using Kruskal-
Wallis for continuous variables and chi-squared for categorical vari-
ables. Statistical analyses were carried out using r version 3.4.2.
We used a landmark analysis that aims to estimate the time-to-
event probabilities in each exposure category, conditional on the 
exposure status of patients at the landmark time (Figure 1).23 In a 
landmark analysis, the point at which we evaluate the exposure sta-
tus of patients is fixed and the analysis is limited to patients who have 
F I G U R E  1   Overview of assessment of exposure to opioids and outcomes including HE and non-HE decompensation events. All patients 
enrolled in the IQVIA Pharmetrics database with at least two ICD-9 codes for cirrhosis were included in the cohort. There was a 1-y look-
back period prior to cirrhosis diagnosis during which covariates and exclusion criteria were assessed. Patients aged 18-64 y with continuous 
health enrolment/pharmacy benefits and no decompensation events were included. Exposure to opioids was assessed in the 6 mo after 
cirrhosis diagnosis. In the year after the exposure assessment period (ie 6 mo-1 y after cirrhosis diagnosis), patients were assessed for the 
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not yet experienced our outcome of interest (HE) by the landmark 
time, which was set at 6 months after cirrhosis diagnosis. We thus 
exclude all patients who experience HE before the landmark time and 
ignore all opioid claims after the landmark time. As a result, this anal-
ysis reduces the risk of bias resulting from a patient's opioid classifi-
cation changing through the course of the follow-up time and ensures 
a uniform exposure assessment for patients who do and do not de-
velop HE. In addition, this approach limits confounding by indication 
that may occur if patients receive opioids for an event that increases 
their likelihood of HE, such as a surgical procedure. Furthermore, this 
approach limits inclusion of patients prescribed lactulose for opi-
oid-induced constipation or prescribed opioids and, as a result, given 
lactulose or rifaximin for primary prophylaxis against HE. Lastly, we 
chose to censor follow-up data at 1-year after the landmark time, 
since HE events that occur >1 year after an opioid prescription are 
unlikely to be related to this prescription.
We used multivariable Cox proportional hazards regression to 
assess associations between opioid use and development of HE, ad-
justing for age, sex, region, cirrhosis aetiology, depression, Charlson 
comorbidity index (CCI) and prior opioid use. We also performed 
multivariable Cox proportional hazards regression to assess the as-
sociation between opioid use and non-HE decompensation events. 
These covariates were chosen a priori based on their potential asso-
ciation with both opioid use and development of HE.
3  | RESULTS
3.1 | Baseline characteristics and opioid use
The cohort included 6451 patients without any decompensation 
events within 1 year prior to cirrhosis diagnosis (Figure 2). The median 
age at cirrhosis diagnosis was 54 years (p25-p75 49-58) and 57.9% were 
male. Other baseline patient characteristics can be found in Table 1.
Overall, 1806 patients (28.0%) were prescribed opioids during the 
6 months after cirrhosis diagnosis. Among this group, the median cu-
mulative days of opioids prescribed was 8 days (p25-p75 2-40). Short-
term opioids were used by 1505 patients (23.3%) and chronic opioids 
were used by 301 patients (4.7%). The median duration of use was 5 
and 153 days among short-term and chronic opioid prescriptions re-
spectively. The most common opioids used were oxycodone, tramadol 
and fentanyl. Those with short-term and chronic opioid prescriptions 
had a higher proportion of female patients, non-ALD aetiology, CCI >2, 
diabetes mellitus and depression (Table 1).
3.2 | Development of hepatic encephalopathy
Over a 1-year follow-up period, 250 (3.9%) of the cohort developed 
HE (Table 2). HE incidence was highest among those with chronic 
opioid prescriptions (6.3%) compared to short-term opioids (5.0%) 
and no opioids (3.3%) (Figure 3). In the multivariable Cox propor-
tional hazards model, both short-term opioid prescriptions (adjusted 
HR 1.44, 95% CI 1.07-1.94) and chronic opioid prescriptions (ad-
justed HR 1.83, 95% CI 1.07-3.12) were significantly associated with 
the risk of hepatic encephalopathy.
For our sensitivity analysis using a 3-month exposure period, the 
rates of HE between 3 and 18 months after index remained higher 
among opioid users (5.3%) compared to non-opioid users (4.9%) but 
this difference was not statistically significant in the multivariable 
model (adjusted HR 1.17, 95% CI 0.96-1.44). When using a 9-month 
exposure period, HE rates from 9 to 21 months after index were 
lowest among those without opioid prescriptions (n = 120, 3.0%) 
compared to those with short-term (n = 66, 5.2%) and chronic 
prescriptions (n = 16, 5.1%). In the multivariable Cox proportional 
hazards models, opioid use was significantly associated with HE 
among short-term users (AHR 1.73, 95% CI 1.26-2.33) but not sig-
nificantly associated among chronic users (AHR 1.54, 95% CI 0.91-
2.62), although the direction of the association remained. Lastly, in 
the sensitivity analysis excluding tramadol and propoxyphene from 
the exposure definition there remained a statistically significant 
association between opioid use and HE among paitents with both 
short-term opioids (adjusted HR 1.88, 95% CI 1.43-2.46) and chronic 
opioids (adjusted HR 2.34, 95% CI 1.59-3.44).
In all sensitivity analyses of positive and negative controls, both 
levels of opioid use remained significantly associated with HE, while 
prescriptions for gabapentin only (adjusted HR 1.68, 95% CI 0.62-
4.59), tricyclic antidepressants only (adjusted HR 0.90, 95% CI 0.44-
1.86), levothyroxine only (adjusted HR 1.34, 95% CI 0.49-3.64) and 
statins only (adjusted HR 0.74, 95% CI 0.39-1.41) were not signifi-
cantly associated with the development of HE. Benzodiazepines 
only were associated with a significantly increased risk of HE in the 
unadjusted analysis (HR 1.77, 95% CI 1.17-2.68) but the association 
was not statistically significant in the multivariable model (adjusted 
HR 1.51, 95% CI 0.98-2.31).
When excluding all patients with an opioid prescription within 
6 months prior to cirrhosis diagnosis, the associations remained di-
rectionally similar and significant for short-term opioid use (adjusted 
HR 1.47, 95% CI 1.03-2.09) but was no longer statistically significant 
for chronic opioid use (adjusted HR 1.55, 95% CI 0.38-6.30).
There were no missing data for the unadjusted models examining 
the association between opioid prescriptions and HE. For adjusted 
models, there were 306 missing observations (4.7%) for our primary 
analysis and all subgroup analyses. Individuals with missing data 
were excluded from these models.
3.3 | Other decompensation events
Overall, 771 patients (12.0%) also developed non-HE decompen-
sation events over 1 year, with similar rates among those with no 
opioid prescriptions (12.0%), short-term opioids (12.0%) and chronic 
opioids (11.6%) (Figure 4). These non-HE decompensation events 
included 718 with ascites, 385 with variceal haemorrhage, 13 with 
spontaneous bacterial peritonitis and eight with hepatorenal syn-
drome. In the multivariable Cox proportional hazards models, neither 
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short-term opioids (adjusted HR 0.96, 95% CI 0.80-1.16) nor chronic 
opioids (adjusted HR 0.93, 95% CI 0.64-1.35) were associated with 
a statistically significantly increased risk of non-HE decompensation 
events.
4  | DISCUSSION
In this nationwide cohort of privately insured patients with cirrhosis, 
both short-term and chronic opioid prescriptions were independently 
associated with an increased risk of HE. Our study provides several 
novel findings. First, 28% of cirrhosis patients received opioids and that 
the annual incidence of HE development was 1.9-fold higher among 
patients with chronic opioid prescriptions compared to those with no 
opioid prescriptions. Second, the liver-specific morbidity of opioids was 
limited to HE, and not other decompensation events. These findings 
suggest that opioids, particularly when used chronically, may not be 
safe even in younger patients with well-compensated cirrhosis.
4.1 | Opioids are uniquely unsafe in cirrhosis
These data expand the literature on the risks of opioids in cirrhosis in 
multiple ways. First, using positive and negative controls, we showed 
that the risk of HE was specific to opioid exposure, decreasing 
concern for confounding by indication. Second, there was no as-
sociation between opioid prescriptions and other decompensation 
events, suggesting that our results were not confounded by the se-
verity of liver disease. In other words, if opioid use was more fre-
quent in patients with more advanced cirrhosis, we would expect all 
decompensation events to be associated with opioid prescriptions. 
Third, we found that these associations are present even among 
younger patients with well-compensated cirrhosis.
Our findings add to the data from Medicare demonstrating that 
opioids are associated with an increased risk of HE.14 This Medicare 
study included a much older population than our current study and 
did not limit their population to those with well-compensated cir-
rhosis. Our findings demonstrate that this potential harm of opioids 
extends to younger patients with well-compensated cirrhosis.
4.2 | Implications of these findings
In light of the association between opioids and HE, providers should 
explore nonpharmacologic and non-opioid options for pain control. 
Exercise, including resistance training, might be a particularly attrac-
tive nonpharmacologic strategy for pain control given that it improves 
muscle mass and combats sarcopenia, which is associated with the 
development of HE and poor outcomes in those with cirrhosis.4,24-28 
Topical therapies like capsaicin and low-dose acetaminophen (≤2 g/
F I G U R E  2   Flow diagram of cirrhosis patients including in our analysis cohort. The cohort included patients with at least two ICD-9 
codes for cirrhosis with sufficient insurance/pharmacy coverage, a 12-mo look-back, no decompensation events during the look-back and 
no episodes of HE during the 6 mo after cirrhosis index date. Our final cohort included 6451 well-compensated cirrhosis patients who were 
followed for 6 mo to assess their exposure to opioids and then for a further 1 yr to assess for the development of incident HE
Excluded:
- 27 659 333 patients without ≥2 ICD-9 codes for
  cirrhosis
- 46 969 patients without ≥12 mo of
  continuous enrolment with pharmacy benefits
- 36 766 with <2 cirrhosis codes b/w age 18-64
- 22 402 patients without ≥12 mo of look-
  back time prior to cirrhosis diagnosis
- 19 020 patients with a decompensation event in
  the 12 mo look-back period
- 4240 without 18 mo of follow-up after
  cirrhosis index date or with HE within 6 mos of
  index date
- 3587 who had a liver transplant code
- 1255 patients who only had PBC codes for
cirrhosis 
27 800 023 commercially-
insured patients within IMS
database 
6451 well-compensated
cirrhosis patients with full
follow-up 
6 mo
4645 (72.0%) with no
opioid use
1505 (23.3%) with short
term opioid use
301 (4.7%) with chronic
opioid use
6 mo6 mo
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day) should be considered the first-line analgesic options for patients 
with cirrhosis given their low risk of harms. Additional studies are 
needed of other analgesics, including gabapentin, which has uncertain 
efficacy and potential harms, especially in patients with cirrhosis.13
The high incidence of HE among chronic opioid users in our co-
hort reinforces the importance of minimising the duration of opioid 
use when they are needed. This is particularly important given the 
uncertain effectiveness of chronic opioids for treating pain.29 When 
opioids are required in patients with cirrhosis, providers should 
maintain a high vigilance for identifying HE. Despite recommenda-
tions to screen patients with cirrhosis for covert HE (a precursor to 
overt HE that can be treated with lactulose or rifaximin) most pa-
tients do not receive this screening.30,31 Given our findings, provid-
ers could consider screening well-compensated cirrhosis patients on 
opioids for overt hepatic encephalopathy with point of care appli-
cations like the EncephalApp Stroop smartphone App or the four 
validated questions of the Sickness Index Profile followed by formal 
psychometric testing.32-34
4.3 | Study strengths and limitations
This study has many strengths including its large, nationwide co-
hort of privately insured individuals. Moreover, we provided a 
novel examination of the potential risks of opioids among younger 
patients with no recent decompensation events. However, our 
findings must be interpreted in the context of this study's poten-
tial limitations.
First, given the lack of laboratory values in our data set, we were 
unable to compute model for end-stage liver disease or Child-Pugh 
Turcotte scores in order to account for the severity of liver disease. 
To mitigate this limitation, we restricted the cohort to those with 
well-compensated cirrhosis. Relatedly, there is the potential for 
confounding introduced as a result of increased opioid use among 
patients with more severe liver disease or other unmeasured con-
founders common to patients with pain. However, the use of land-
mark analysis, the lack of association between positive/negative 







(n = 301) P-valuea
Age, y (median, 
p25-p75)
54 (49-58) 53 (48-58) 53 (50-58) 0.092
Male Sex 2786 (60.0) 774 (51.4) 175 (58.1) <0.001
Region
East 912 (19.6) 244 (16.2) 49 (16.3) 0.024
Midwest 1388 (29.9) 455 (30.2) 68 (22.6)
South 1372 (29.5) 377 (25.0) 60 (19.9)
West 973 (20.9) 429 (28.5) 124 (41.2)
CCI (%)
1 2244 (48.3) 540 (35.9) 95 (31.6) <0.001
2 1303 (28.1) 465 (30.9) 87 (28.9)
>2 1098 (23.6) 500 (33.2) 119 (39.5)
Depression 508 (10.9) 254 (16.9) 74 (24.6) <0.001
Diabetes mellitus 1154 (24.8) 462 (30.7) 94 (31.2) <0.001
Cirrhosis aetiology
ALD 747 (16.1) 222 (14.8) 27 (9.0) <0.001
Viral hepatitis 1660 (35.7) 509 (33.8) 139 (46.2)
Other 2238 (48.2) 774 (51.4) 135 (44.9)
TCA use 224 (4.8) 158 (10.5) 47 (15.6) <0.001
Statin use 392 (8.4) 194 (12.9) 32 (10.6) <0.001
Levothyroxine use 92 (2.0) 40 (2.7) 9 (3.0) 0.183
Gabapentinoid use 59 (1.3) 50 (3.3) 37 (12.3) <0.001
Benzodiazepine use 498 (10.7) 283 (18.8) 111 (36.9) <0.001
Prior opioidsb 701 (15.1) 607 (40.3) 261 (86.7) <0.001
Note: Values within parenthesis are expressed in % and/or p25-p75.
Abbreviations: ALD, alcohol-related liver disease; CCI, Charlson Comorbidity Index; TCA, tricyclic 
antidepressant.
aBivariate comparison via Kruskal-Wallis test for continuous variables and chi-squared for 
categorical variables. 
bOpioid prescription in the year prior to cirrhosis diagnosis. 
TA B L E  1   Baseline patient 
characteristics by opioid use status
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decompensation events within opioid groups all provide reassurance 
against confounding.
Given that our outcome definitions relied on ICD codes and 
medication prescription data, there is a possibility of misclassi-
fication of HE cases and other decompensation events. For in-
stance, it may be that opioid-induced altered mental status is 
being misdiagnosed as HE. However, the annual incidence of HE 
and other decompensation events are comparable to what has 
been published in the literature, providing external validity to our 
results.15,35-38 In addition, any event prompting a billing code for 
HE or the initiation of lactulose/rifaximin is likely to be clinically 
important. Furthermore, the separation of exposure and outcome 
assessment through the landmark analysis limits the inclusion of 
episodes of altered mental status occurring immediately after 
opioid initiation, patients who were treated with lactulose for 
opioid-induced constipation or put on lactulose or rifaximin as 
HE prophylaxis after being started on opioids. Lastly, a 6-month 
exposure period was chosen a priori to reduce the risk of a type 
II error, confounding by indication and misclassification of opioid 
use. While the sensitivity analyses using exposure periods of 3 
and 9 months had some nonsignificant results, the direction of 
these associations remained and we suspect these were due to 
misclassification of opioid use and type II error respectively.
5  | CONCLUSION
In this national study of younger, privately insured patients with cir-
rhosis and no recent decompensation events, prescriptions for opi-
oids were associated with HE. In light of this potential harm of opioid 
TA B L E  2   Association between opioids and positive/negative controls on hepatic encephalopathy
 Number of patients (%)
Number who developed 
HE/1 y (%) Crude HR (95% CI)
Adjusted HRa (95% 
CI)
Opioids
No opioids 4645 (72.0) 155 (3.3) Ref. Ref.
Short-term opioids 1505 (23.3) 76 (5.0) 1.53 (1.16-2.01) 1.44 (1.07-1.94)
Chronic opioids 301 (4.7) 19 (6.3) 1.94 (1.20-3.12) 1.83 (1.07-3.12)
Gabapentin
No opioids or gabapentin 4586 (71.1) 151(3.3) Ref. Ref.
Short-term opioids 1505 (23.3) 76 (5.0) 1.55 (1.17-2.04) 1.46 (1.08-1.97)
Chronic opioids 301 (4.7) 19 (6.3) 1.96 (1.22-3.16) 1.86 (1.09-3.19)
Gabapentin only 59 (0.9) 4 (6.8) 2.10 (0.78-5.68) 1.68 (0.62-4.59)
Tricyclic antidepressants
No opioids or tricyclic 
antidepressants
4421 (68.5) 147 (3.3) Ref. Ref.
Short-term opioids 1505 (23.3) 76 (5.0) 1.53 (1.16-2.02) 1.43 (1.06-1.94)
Chronic opioids 301 (4.7) 19 (6.3) 1.94 (1.21-3.13) 1.81 (1.06-3.11)
Tricyclic antidepressants only 224 (3.5) 8 (3.6) 1.08 (0.53-2.20) 0.90 (0.44-1.86)
Levothyroxine
No opioids or levothyroxine 4553 (70.6) 151 (3.3) Ref. Ref.
Short-term opioids 1505 (23.3) 76 (5.0) 1.53 (1.17-2.03) 1.45 (1.08-1.96)
Chronic opioids 301 (4.7) 19 (6.3) 1.95 (1.21-3.14) 1.84 (1.08-3.14)
Levothyroxine only 92 (1.4) 4 (4.3) 1.34 (0.50-3.62) 1.34 (0.49-3.64)
Statins
No opioids or statins 4253 (65.9) 145 (3.4) Ref. Ref.
Short-term opioids 1505 (23.3) 76 (5.0) 1.49 (1.13-1.97) 1.40 (1.04-1.90)
Chronic opioids 301 (4.7) 19 (6.3) 1.89 (1.17-3.06) 1.78 (1.04-3.05)
Statins only 392 (6.1) 10 (2.6) 0.75 (0.39-1.41) 0.74 (0.39-1.41)
Benzodiazepines
No opioids or benzodiazepines 4147 (64.3) 128 (3.1) Ref. Ref.
Short-term opioids 1505 (23.3) 76 (5.0) 1.65 (1.24-2.19) 1.54 (1.13-2.09)
Chronic opioids 301 (4.7) 19 (6.3) 2.09 (1.29-3.39) 1.95 (1.14-3.35)
Benzodiazepines only 498 (7.7) 27 (5.4) 1.77 (1.17-2.68) 1.51 (0.98-2.31)
aAdjusted for age, sex, region, cirrhosis aetiology, depression, Charlson comorbidity index (CCI) and prior opioid use. 
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prescriptions, these medications should be avoided when possible 
even in patients with well-compensated cirrhosis. When opioid use 
is required, it should be short duration and clinicians should maintain 
a high vigilance for detecting HE. These associations could also be 
further explored with prospective studies of the safety of opioids in 
patients with cirrhosis and additional study investigating the mecha-
nisms linking opioids and HE.
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